Axi-cel improves survival in early r/r large B-cell lymphoma

ZUMA-7: Axi-cel in r/r large B-cell lymphomaПодробнее

Standard-of-care setting results of axi-cel in R/R large B-cell lymphomaПодробнее

Axi-cel as second-line therapy for R/R large B-cell lymphomaПодробнее

The value of axi-cel as a second-line treatment in R/R LBCLПодробнее

ZUMA-1 update: durable survival in R/R DLBCL patients treated with axi-celПодробнее

Where Does Axi-Cel Fit in Large B-Cell Lymphoma Treatment?Подробнее

Updates from ZUMA-7: axi-cel for R/R DLBCLПодробнее

Primary overall survival analysis of the ZUMA-7 trialПодробнее

Real-world data on axi-cel for patients with large B-cell lymphomaПодробнее

Axi-cel in patients with R/R LBCL in complete metabolic responseПодробнее

Clinical Data for Axi-Cel in LymphomaПодробнее

ZUMA-7: overall survival benefit of axi-cel over SOC in second-line LBCLПодробнее

Radiotherapy bridging for axi-cel in large B-cell lymphomaПодробнее

Frederick Locke on Axi-cel and ZUMA-7Подробнее

Dr. Neelapu Discusses Efficacy of Axi-Cel in Large B-Cell LymphomaПодробнее

Is Axi-Cel in Second Line the New Standard in Aggressive B-Cell Lymphoma? - Medpage TodayПодробнее

Axi-cel plus rituximab for R/R LBCL and updates from the ZUMA-14 studyПодробнее

ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphomaПодробнее

Shorter time from leukapheresis to infusion of axi-cel shows better CR and OS in r/r LBCLПодробнее